Insulet (PODD) Receives a Buy from Bernstein
Bernstein analyst Lee Hambright maintained a Buy rating on Insulet today and set a price target of $380.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Hambright covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Dexcom, and Insulet. According to TipRanks, Hambright has an average return of 6.4% and a 58.59% success rate on recommended stocks.
In addition to Bernstein, Insulet also received a Buy from Wells Fargo’s Larry Biegelsen in a report issued today. However, on January 9, Barclays downgraded Insulet (NASDAQ: PODD) to a Sell.
Based on Insulet’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $706.3 million and a net profit of $87.6 million. In comparison, last year the company earned a revenue of $543.9 million and had a net profit of $77.5 million
Based on the recent corporate insider activity of 67 insiders, corporate insider sentiment is neutral on the stock. Last month, Frederick Wayne A.I. , a Director at PODD sold 1,851.00 shares for a total of $542,509.59.
Read More on PODD:
Disclaimer & DisclosureReport an Issue
- Netflix initiated, Palantir upgraded: Wall Street’s top analyst calls
- Barclays downgrades Insulet to Underweight on intensifying competition
- Insulet downgraded to Underweight from Equal Weight at Barclays
- Insulet price target lowered to $380 from $410 at Bernstein
- Insulet price target lowered to $365 from $388 at Goldman Sachs
